Evolocumab (Repatha), a human monoclonal antibody and proprotein convertase subtilisin/kexin type 9 inhibitor, produced positive results in persons living with HIV in the BEIJERINCK study by ...

The difference in QALY was 0.39, with an ICER of $268,637 gained following the addition of evolocumab. Furthermore, the evolocumab treatment exceeded $150,000 per QALY in most scenarios.

The PCSK9 monoclonal antibody evolocumab (Repatha, Repatha Repatha Amgen) was well tolerated and effectively lowered LDL cholesterol by 38% compared with placebo in a randomized controlled trial ...

Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or “bad” cholesterol, also significantly lowers the ...

Evolocumab is prescribed as an adjunct to a low-fat diet and other cholesterol medications in treating patients with high low-density lipoprotein (LDL) cholesterol, total cholesterol, heterozygous ...

PARIS — In the first randomized trial designed to assess a PCSK9 inhibitor in patients with high-risk ACS, the addition of evolocumab to statin therapy was well tolerated and substantially ...

Evolocumab generic Evolocumab is prescribed as an adjunct to a low-fat diet and other cholesterol medications in treating patients with high low-density lipoprotein (LDL) cholesterol, total ...

If evolocumab was discounted 29% to $10,311, the ICER is $165,689 per QALY gained, which is still above the threshold considered cost-effective. To achieve an ICER of $150,000, $100,000, and $50,000 ...

This should reassure both patients and physicians that prescribing evolocumab leads to a “consistent reduction in LDL cholesterol,” Qamar said. Payers should also be confident enough to know that when ...

Patients assigned evolocumab had LDL reductions of 63% to 75% compared with placebo at a mean of weeks 10 and 12, while those assigned ezetimibe had LDL reductions of 19% to 32% compared with ...

(MENAFN- GetNews) "PCSK9 Inhibitors Market"The PCSK9 Inhibitors market size reached ~USD 2 billion in 2023 in 7MM and is ...

Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or "bad" cholesterol, also significantly lowers the ...